MiNK Therapeutics (INKT) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
INmune Bio (INMB) has outperformed MiNK Therapeutics (INKT) over the past year, losing 9.0% versus a loss of 24.6%. Over five years, INMB leads with a -90.2% price change compared with -90.8% for INKT. MiNK Therapeutics is the larger company by market cap ($56.1 million vs $50.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INKT | INMB |
|---|---|---|
| Share price | $11.00 | $1.83 |
| Market cap | $56.13M | $50.79M |
| 1-day change | -3.68% | -1.61% |
| YTD return | -1.35% | +17.31% |
| 1-year return | -24.61% | -8.96% |
| 5-year return | -90.83% | -90.17% |
| EPS (TTM) | $-2.39 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $2.60 |
| 52-week low | $8.48 | $1.09 |
| Distance from 52-week high | -35.02% | -29.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +254.55% | +282.51% |
| Average volume | 13.80K | 402.12K |
| Shares outstanding | 5.10M | 27.75M |
| Employees | 15 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed INKT by 15.7 percentage points over the past year.
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Healthcare · Biotechnology · 15 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Healthcare · Biotechnology · 21 employees
INKT vs INMB FAQ
Which is bigger, MiNK Therapeutics or INmune Bio?
MiNK Therapeutics (INKT) is larger, with a market capitalization of $56.13M compared with $50.79M for INmune Bio (INMB).
Which stock has performed better over the past year, INKT or INMB?
INMB returned -8.96% over the past 12 months, compared with -24.61% for INKT (price return, excluding dividends). Past performance does not predict future results.
Are MiNK Therapeutics and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.